OliveSEcksteinMD
Pediatric Hematology & Oncology • Houston, TXCancer Genetics/Cancer Risk Assessment, Pediatric Hematologic Oncology
Assistant Professor
Dr. Eckstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6701 Fannin St
Houston, TX 77030Phone+1 832-824-1000
Summary
- Dr. Olive Eckstein is a pediatric hematologist/oncologist in Houston, TX and is affiliated with Texas Children's Hospital. She received her medical degree from Chicago Medical School at Rosalind Franklin University and has been in practice for over 10 years. She specializes in histiocytic disorders (including HLH, LCH, Rosai-Dorfman disease, juvenile xanthogranuloma), lymphomas, lymphoproliferative disorders, cancer genetics, and pediatric hematologic oncology and is experienced in general pediatric hematology-oncology and pediatric hematopoietic stem cell transplantation.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2011 - 2014
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2007 - 2010
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2007
Certifications & Licensure
TX State Medical License 2014 - 2025
OH State Medical License 2010 - 2013- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha
Clinical Trials
- Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) Start of enrollment: 2016 Mar 07
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Start of enrollment: 2021 Apr 19
- Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Start of enrollment: 2021 Jul 13
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review St...Shanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, John Carter, May Chien
Arthritis & Rheumatology. 2024-09-08 - Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.Kevin Bielamowicz, Peter Dimitrion, Oussama Abla, Simon Bomken, Patrick Campbell
Cancer. 2024-07-15 - 2 citationsReal-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.Shanmuganathan Chandrakasan, Michael B Jordan, Ashley Baker, Edward M Behrens, Deepika Bhatla
Blood Advances. 2024-05-14
Abstracts/Posters
- Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma CohortOlive S. Eckstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphoh...Olive S. Eckstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Committees
- Committee Member, American Academy of Pediatrics (AAP) Committee on Drugs 2023 - Present
Professional Memberships
- Member
- Histiocyte SocietyMember
- ASPHOMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
